Floatz logo

Pembrolizumab

Kidney Neoplasm

Syndax Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Kidney Neoplasm cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →